April 11 news, medical instant diagnostic equipment R & D manufacturer Huamai Xingwei announced that it has completed 50 million yuan A + round of financing, led by Shenzhen Yingtai Yukang Venture Capital Partnership (Limited Partnership), Shanghai Powerway Yicheng Investment (Group) Co., Ltd. and Shandong Jiangyan Venture Capital Co., Ltd. voted.
Mr. Li Quan, Chairman of Huamai Xingwei, said, “This round of financing is mainly used for the production and sales of micro-chemiluminescence analyzers (M2), product development and reporting of M5, M7, MD01 instrument series and more clinical reagents. Huamai Xingwei will further increase product research and development and registration declaration, enrich the types of reagents to be certified, open up new markets and opportunities, and contribute to China's POCT business."
Established in December 2014, Huamai Xingwei is principally engaged in the research and development, production and sales of chemical immunoassay, analyzers and supporting cardiovascular disease marker reagent cards for medical instant diagnostic equipment. It is reported that Huamai Xingwei has obtained millions and tens of millions of angel rounds and A rounds of financing in 2015 and 2016 respectively. The investors include Yuanhe Holdings, Zhongxing Hechuang and Kaiying Capital, and Dachen Venture Capital.
As a manufacturer of micro-chemiluminescence analyzers, the “Aurora†M2 microfluidic chemiluminescence analyzer developed by Huamai Xingwei has the three core technologies of “microfluidic control + magnetic particle separation + POCTâ€. It is the first in the world. The microfluidic chemiluminescence analysis system features precise detection, miniaturization, and fooling. It weighs only 5KG, and the accuracy of the test results is comparable to that of large-scale chemiluminescence inspection equipment.
The current investor Shenzhen Yingtai Yukang Venture Capital Partnership (Limited Partnership) is a national medical industry guidance fund. The funders include the National Development and Reform Commission, Shenzhen Guiding Fund Investment Co., Ltd., and Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. , China's Yinhong, etc., the management fund size of about 5 billion yuan. He has a professional investment team, rich investment management and operational experience in biomedicine, pension and real estate. In the future, the two sides have broad cooperation space in the direction of high-quality antibody raw material supply, heart failure/cardiovascular and cerebrovascular drug concomitant treatment, elderly health checkup, chronic disease management, and immune cell storage accompanying detection.
Moisturizing Cosmetic Ingredients
Youth Biotech CO,. Ltd. , https://www.youtherb.com